Triptan safety during pregnancy: a Norwegian population registry study
- 911 Downloads
Knowledge on triptan safety during pregnancy remains limited to their class effect or studies on sumatriptan. Our aim was to evaluate the individual effect of four most frequently used triptans on several pregnancy outcomes. We used the Norwegian prescription database to access information on triptans redeemed by pregnant women living in Norway between 2004 and 2007. This database was linked to the Medical Birth Registry of Norway covering every institutional delivery in Norway and providing information on pregnancy, delivery, maternal and neonatal health. Estimates of associations with pregnancy outcomes were obtained by Generalised Estimation Equations analysis. Of the 181,125 women in our study, 1,465 (0.8 %) redeemed triptans during pregnancy, and 1,095 (0.6 %) redeemed triptans before pregnancy only (disease comparison group). The population comparison group comprised the remaining 178,565 women. Using this group as reference, we found no associations between triptan redemption during pregnancy and congenital malformations. Second trimester redemption was associated with postpartum haemorrhage (adjusted OR 1.57; 95 % CI 1.19–2.07). The disease comparison group had an increased risk of major congenital malformations (adjusted OR 1.48; 95 % CI 1.11–1.97), low birth weight (adjusted OR 1.39; 95 % CI 1.08–1.81), and preterm birth (adjusted OR 1.30; 95 % CI 1.06–1.60). The association of triptans with postpartum hemorrhage could be attributable to decreased platelet agreeability occurring in severe migraine. Likewise, the increased risk of major congenital malformations and other adverse pregnancy outcomes in the disease comparison group might be attributable to migraine severity.
KeywordsTriptans Migraine Pregnancy Congenital malformations Adverse pregnancy outcomes
- 10.Cripe SM, Frederick IO, Qiu C, Williams MA. Risk of preterm delivery and hypertensive disorders of pregnancy in relation to maternal co-morbid mood and migraine disorders during pregnancy. Paediatr Perinat Epidemiol. 2011;25(2):116–23. doi: 10.1111/j.1365-3016.2010.01182.x.PubMedCrossRefGoogle Scholar
- 15.Leveno KJ, Cunningham FG, Alexander JM, Bloom SL, Casey BM, Dashe JS, et al. Williams manual of obstetrics pregnancy complications. 22nd ed. New York: McGraw-Hill; 2007.Google Scholar
- 18.Nezvalova-Henriksen K, Spigset O, Nordeng HM. Errata in “Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the norwegian mother and child cohort study”. Headache. 2012;52(8):1319–20. doi: 10.1111/j.1526-4610.2012.02207.x.PubMedCrossRefGoogle Scholar
- 23.GlaxoSmithKline. The Sumatriptan/Naratriptan/Treximet Pregnancy. 2012.Google Scholar
- 24.Norwegian Institute of Public Health. The Medical Birth Registry of Norway. Oslo, Norway. http://www.fhi.no/helseregistre/medisinsk-fodselsregister (2013).
- 25.Norwegian Institute of Public Health. The Norwegian Prescription Database. Oslo, Norway. http://www.fhi.no/helseregistre/reseptregisteret (2013).
- 30.Baghestan E, Bordahl PE, Rasmussen SA, Sande AK, Lyslo I, Solvang I. A validation of the diagnosis of obstetric sphincter tears in two Norwegian databases, the Medical Birth Registry and the Patient Administration System. Acta Obstet Gynecol Scand. 2007;86(2):205–9. doi: 10.1080/00016340601111364.PubMedCrossRefGoogle Scholar
- 32.ATC/DDD Index 2008 [database on the Internet]. Available from: < http://www.whocc.no/atcddd/> (2009). Accessed 3 June 2009.
- 33.World Health Organization. International Classification of Diseases. 2013. http://www.who.int/classifications/icd/en/.
- 38.Gupta S, Hanff LM, Visser W, Steegers EA, Saxena PR, Vulto AG, et al. Functional reactivity of 5-HT receptors in human umbilical cord and maternal subcutaneous fat arteries after normotensive or pre-eclamptic pregnancy. J Hypertens. 2006;24(7):1345–53. doi: 10.1097/01.hjh.0000234115.40648.88.PubMedCrossRefGoogle Scholar